A closer look into the IBSA World is the new series dedicated to discovering IBSA’s subsidiaries. With this news cycle we aim to offer an overview of the initiatives and challenges undertaken by IBSA subsidiaries in their local context, emphasising the diversity and operational scope at an international level.
Today’s protagonists are the USA, a vital hub for a dynamic and expanding pharmaceutical company like IBSA.
Through their outspoken resourcefulness, Americans face challenges springboarding towards new opportunities, guided by their distinguishing optimism and pragmatism.
It is precisely with this vivacity that IBSA USA is constantly evolving its position in the pharmaceutical market by expanding its product portfolio. With an approach measured by the specificities of the American scenario, the US subsidiary has been able to stand out, thanks to several factors:
The all-American spirit for adventure – which began in Parsippany (New Jersey) in 2018 – and the clear determination to achieve objectives brought this cohesive and enterprising team towards significant growth. But the US market is still very large.
Nicholas Hart, CEO of IBSA USA, offers us his testimony:
The positioning of IBSA USA in its perception market – i.e. the reference that patients and doctors have of the company and its products – is closely related to its scientific approach, its clinical studies and the synergy among the Headquarters Research & Development in Lugano, the Washington DC Research & Development department, and the US commercial Headquarters in Parsippany, NJ.
Commercial strategies – also coordinated with the international team – aim to ensure a progressive and robust growth, with the awareness that the United States represents a great opportunity for the entire Group.
Already active in the areas of endocrinology, osteoarticular and pain & inflammation, IBSA USA is preparing to launch a product within the reproductive medicine area, capitalising on the experience acquired by the Headquarters and other subsidiaries.
A prominent scientific profile and clear strategy and goals: a combination with a great potential, made even stronger by a distinguishing, rigorous and accurate communication.
The strength of IBSA products – as noted by Nicholas Hart – resides in their uniqueness, functionality and effectiveness. These factors are well communicated by the American subsidiary, with a particular focus on medical specialists, primary care physicians, nurses, and medical assistants. Additionally, IBSA USA participates in industry conferences and organises conventions and events aimed at involving key opinion leaders, health professionals and the specialised press.
Another key factor is product communication aimed at patients. Unlike European countries, in fact, in the United States the regulations allow direct communication with the public even in the case of prescription drugs. Currently, IBSA USA has several on-going initiatives and is planning new projects and information campaigns.
Last May 11, the IBSA USA team had the privilege to welcome Alberto Bona – the skipper who represents the project Sailing into the Future. Together – at the end of the solo regatta, Transat CIC, which he completed on board the Class40 IBSA. Started from Lorient, France, the regatta finished in New York, just under an hour’s drive from the IBSA USA headquarters in Parsippany.
This project embodies the values of IBSA with regard not only to the sporting challenge, but also to the Company’s commitment to inclusive sailing, which – after several initiatives launched in Switzerland, France, Italy and Spain – is now expanding to the United States. The American subsidiary has in fact decided to support the organisation Sail To Prevail, a sailing club based in Newport, Rhode Island, which every year organises sailing-related activities for over 1,500 children and adults with disabilities.
Back to top
